Belite Bio, Inc (BLTE)
NASDAQ: BLTE · Real-Time Price · USD
69.71
-0.19 (-0.27%)
Nov 4, 2024, 4:00 PM EST - Market closed
Belite Bio Employees
Belite Bio had 20 employees as of December 31, 2023. The number of employees increased by 4 or 25.00% compared to the previous year.
Employees
20
Change (1Y)
4
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,764,500
Market Cap
2.13B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 20 | 4 | 25.00% |
| Dec 31, 2022 | 16 | 4 | 33.33% |
| Dec 31, 2021 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CONMED | 4,000 |
| Omnicell | 3,650 |
| Warby Parker | 3,473 |
| UFP Technologies | 3,093 |
| GeneDx Holdings | 1,000 |
| LeMaitre Vascular | 630 |
| Vericel | 314 |
| Wave Life Sciences | 268 |
BLTE News
- 1 day ago - Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds - GlobeNewsWire
- 2 months ago - Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer - GlobeNewsWire
- 3 months ago - Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 3 months ago - Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - GlobeNewsWire
- 3 months ago - Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results - GlobeNewsWire
- 5 months ago - Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan - GlobeNewsWire
- 6 months ago - Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript - Seeking Alpha